Skip to main content
Premium Trial:

Request an Annual Quote

Intrexon to Complete Acquisition of Exemplar Genetics

NEW YORK (GenomeWeb) – Intrexon today announced a tender offer of an undisclosed amount for the remaining 49 percent stake of Exemplar Genetics.

Intrexon received a partial stake in Exemplar when it acquired cattle genetics firm Trans Ova Genetics for $110 million in July 2014. Trans Ova owned an approximately 51 percent stake in Exemplar, according to a Form 10-Q filed by Intrexon in November with the US Securities and Exchange Commission.

Exemplar has created animal models of human disease in transgenic swine for research and development uses. Diseases being researched with the models include heart disease, cancer, cystic fibrosis, cardiac arrhythmia, and neuromuscular and neurodegenerative disorders.

"Disease models enabled by Exemplar's capabilities have the potential to facilitate [the] development of therapeutic solutions, as well as more accurately assess their effectiveness in addressing the underlying causes of rare genetic diseases," Mark Pykett, CEO of Agilis Biotherapeutics, a partner of Intrexon, said in a statement.

Exemplar's research tools will be offered exclusively to Intrexon's channel partners, Intrexon Senior VP Gregory Frost said in a statement. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.